Bittere Pille für Regeneron Pharmaceuticals. Das Unternehmen und der Entwicklungspartner Sanofi haben in der vergangenen Handelswoche mit frischen Spätphasen-Studiendaten zum…
Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) sank nearly 19% on Friday after the company’s experimental COPD drug, developed with partner…
Earlier this year, biotech company 23andMe filed for bankruptcy. The harsh reality was that its business, while enticing to people…
Regeneron Pharmaceuticals said earlier this month that it will acquire "substantially all" of 23andMes assets for $256 million.…
Regeneron is acquiring "substantially all" of 23andMes assets for $256 million following a bankruptcy auction.…
Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people,…
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, the companies said…
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, the companies said…
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has agreed to buy genetic testing company 23andMe for $256 million, two months after the biotech…
Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past few decades, and that the…
New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Oppenheimer:
1. Kurszielanpassung:
Oppenheimer hat das Kursziel für die Aktie von Regeneron Pharmaceuticals Inc. (ISIN:…
TARRYTOWN, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for…
What should investors do during a stock-market correction? One great strategy is to go shopping. A bull market will eventually…
Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug…
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S.…
Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex…
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year,…
Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.…
As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative…
TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will…
Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).…
Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Though the drugmaker had performed well since the…
Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.…
Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the…
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…
Biotech giant Renegeron Pharmaceuticals (NASDAQ: REGN) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The companys results were…
New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Guggenheim Securities:
Aktuelle Bewertung
Die Investmentbank Guggenheim Securities hat ihr Kursziel für die Aktie von…
Investing in stocks that arent performing well can be a good move, but only if there are good reasons to…
NEW YORK, Feb. 09, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized…
NEW YORK, Feb. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc.…
LOS ANGELES, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming…
News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the…
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced…
TARRYTOWN, N.Y., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for…
Investors can contact the law firm at no cost to learn more about recovering their losses…
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To…
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, Jan. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
SAN DIEGO, Jan. 18, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP…
NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc.…
Zürich (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von der UBS:
Aktuelle Bewertung
UBS hat die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…
New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Citigroup:
Rating und Kursziel
Citi hat das Kursziel für die Aktie von Regeneron Pharmaceuticals Inc.…
Robbins LLP is Investigating Allegations that Regeneron Pharmaceuticals, Inc. (REGN) Misled Investors Regarding its Business Prospects…
…
High-yield dividend stocks may not appeal to some investors. However, if youre among those investors looking for income, stocks that…
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of…
Toronto (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von RBC Capital Markets:
RBC Capital Markets hat das Kursziel für die Aktie von Regeneron Pharmaceuticals…